Beneficial effects of Ilex paraguariensis in the prevention of obesity‐associated metabolic disorders in mice

2022 ◽  
Author(s):  
Helber da Maia Valença ◽  
Cyntia Pecli Silva ◽  
Lycia Brito Gitirana ◽  
Samuel Santos Valença ◽  
Manuella Lanzetti
2020 ◽  
Vol 26 (39) ◽  
pp. 4953-4954
Author(s):  
Mallikarjuna Korivi ◽  
Betty Revon Liu

Metabolic syndrome (MetS) which is caused by poor dietary habits and sedentary behavior is a serious global health problem. MetS is a cluster of risk factors, represented by central obesity, hyperglycemia, dyslipidemia, and hypertension. In the 21st century, MetS and associated comorbidities, including obesity, diabetes and cardiovascular diseases, are the major threats to human health. Practical dietary strategies, nutritional bioactive compounds and a healthy lifestyle are claimed to be efficient in the management of one or more components of MetS. Nevertheless successful management of MetS and commodities is still a major concern. Since hyperglycemia, inflammation and redox imbalance are intrinsically involved in the progression of MetS comorbidities, finding effective strategies that precisely target these systems is highly warranted. In this scenario, pharmacological and non-pharmacological approaches with or without dietary patterns, phytochemicals or exercise interventions are the practical strategies to combat MetS and associated diseases. However, designing and prescribing of optimal nutritional patterns and exercise regimens remains a big challenge to achieve the maximum beneficial effects. This thematic issue addressed the concerns and provided practical strategies to overcome the malady of MetS in the modern world.


2021 ◽  
Author(s):  
Qi Guan ◽  
Xinwen Ding ◽  
Lingyue Zhong ◽  
Chuang Zhu ◽  
Pan Nie ◽  
...  

Long term high-fat diet (HF) can cause metabolic disorders, which might induce fatty liver. Fermented whole cereal food exhibit healthy potential due to their unique phytochemical composition and probiotics. In...


Molecules ◽  
2020 ◽  
Vol 25 (11) ◽  
pp. 2693 ◽  
Author(s):  
Carla Maiara Lopes Cardozo ◽  
Aline Carla Inada ◽  
Claudia Andrea Lima Cardoso ◽  
Wander Fernando de Oliveira Filiú ◽  
Bernardo Barcelar de Farias ◽  
...  

There are still controversies regarding the correlation between the beneficial effects for health and the administration of isolated compounds or crude extracts in therapeutic applications. Campomanesia xanthocarpa, found in the Brazilian Cerrado, demonstrated beneficial effects in metabolic disorders associated with obesity. We investigated the effects of Campomanesia xanthocarpa hydroethanolic extract and two isolated substances from the extract (S1 and S2) in a diet-induced obesity (DIO) model. Male Swiss mice were divided into five groups: (1) American Institute of Nutrition (AIN-93M) diet, (2) high-fat diet (HF), (3) HF supplemented with C. xanthocarpa hydroethanolic leaf extract at 100 mg/kg (HFE), (4) HF supplemented with S1 at 1 mg/kg (HFS1) and (5) HF supplemented with S2 at 1 mg/kg (HFS2). The HFS1, HFS2 and HFE groups did not present decreasing body weight or visceral adiposity gain. No differences in glycemic and lipid parameters, or in the expression of protein content in two cytokines, interleukin-6 (IL-6) and anti-inflammatory (IL-10), were observed. Only the HFS1 group displayed decreased food intake. Even though substantial effects such as an improvement in obesity features or the metabolic and histological parameters promoted by S1, S2 and the extract were not observed, further investigations are necessary to evaluate the principal genes and protein expressions involved in regulating food behavior promoted by S1.


2020 ◽  
Vol 8 (9) ◽  
pp. 1413
Author(s):  
Meng Yang ◽  
Shambhunath Bose ◽  
Sookyoung Lim ◽  
JaeGu Seo ◽  
JooHyun Shin ◽  
...  

The identification of new probiotics with anti-obesity properties has attracted considerable interest. In the present study, the anti-obesity activities of Akkermansia muciniphila (A. muciniphila) strains isolated from human stool samples and their relationship with the gut microbiota were evaluated using a high fat-diet (HFD)-fed mice model. Three strains of A. muciniphila were chosen from 27 isolates selected based on their anti-lipogenic activity in 3T3-L1 cells. The anti-lipogenic, anti-adipogenic and anti-obesity properties of these three strains were evaluated further in HFD-induced obese mice. The animals were administered these strains six times per week for 12 weeks. The treatment improved the HFD-induced metabolic disorders in mice in terms of the prevention of body weight gain, caloric intake and reduction in the weights of the major adipose tissues and total fat. In addition, it improved glucose homeostasis and insulin sensitivity. These effects were also associated with the inhibition of low-grade intestinal inflammation and restoration of damaged gut integrity, prevention of liver steatosis and improvement of hepatic function. These results revealed a difference in the distribution pattern of the gut microbial communities between groups. Therefore, the gut microbial population modulation, at least in part, might contribute to the beneficial impact of the selected A. muciniphila strains against metabolic disorders.


Cephalalgia ◽  
2019 ◽  
Vol 39 (5) ◽  
pp. 648-654 ◽  
Author(s):  
Parisa Hajihashemi ◽  
Gholamreza Askari ◽  
Fariborz Khorvash ◽  
Mohammad Reza Maracy ◽  
Mojgan Nourian

Purpose The present study aimed to determine the effects of combined supplementation of Coenzyme Q10 with L-carnitine on mitochondrial metabolic disorders marker and migraine symptoms among migraine patients. Methods A total of 56 men and women, between 20–40 years of age with migraine headache, participated in this randomized, double-blind, placebo-controlled, parallel study. The subjects were randomly assigned to receive either 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine at the same time and/or placebo tablets for 8 weeks. The measurements were completed at the beginning and end of the study. The primary outcome was severity of headache attacks. The secondary outcomes included duration, frequency of headache attacks, the headache diary results (HDR), and serum levels of lactate. Results A significant reduction was obtained in serum levels of lactate (−2.28 mg/dl, 95% CI: −3.65, −0.90; p = 0.002), severity (−3.03, 95% CI: −3.65, −2.40; p ≤ 0.001), duration (−7.67, 95% CI: −11.47, −3.90; p ≤ 0.001), frequency (−5.42, 95% CI: −7.31, −3.53; p ≤ 0.001) and HDR (−103.03, 95% CI: −145.76, −60.29; p ≤ 0.001) after 8 weeks. Conclusion This double-blind parallel study provides evidences supporting the beneficial effects of Coenzyme Q10 and L-carnitine supplements on serum levels of lactate and migraine symptoms. Trial registration IRCT20121216011763N21.


PLoS ONE ◽  
2019 ◽  
Vol 14 (8) ◽  
pp. e0220377 ◽  
Author(s):  
Hana Malinska ◽  
Martina Hüttl ◽  
Olena Oliyarnyk ◽  
Irena Markova ◽  
Martin Poruba ◽  
...  

2013 ◽  
Vol 53 (1) ◽  
pp. 73-82 ◽  
Author(s):  
Natália da S. Lima ◽  
Juliana G. Franco ◽  
Nayara Peixoto-Silva ◽  
Lígia A. Maia ◽  
Andrea Kaezer ◽  
...  

2020 ◽  
Vol 34 ◽  
pp. 7-16
Author(s):  
Estefanía Alcázar ◽  
Silvia Martínez ◽  
Josefa Madrid ◽  
Pablo Larrosa ◽  
Fuensanta Hernández

El objetivo de este trabajo fue realizar una revisión de los efectos derivados del uso de monensina como alternativa para afrontar con mayor éxito el periodo de transición en vacas lecheras. En las vacas de leche, la transición de la preñez al inicio de la lactación es un periodo crítico que se caracteriza por presentar una mayor incidencia de enfermedades. En este periodo, el riesgo de que se presenten trastornos metabólicos y enfermedades está relacionado con el balance energético negativo en el que se encuentra la vaca, hecho que conlleva una movilización de nutrientes desde las reservas tisulares. Una de las posibles soluciones para mejorar el balance de nutrientes durante el período de transición consiste en administrar ionóforos como la monensina que actúan modificando la población microbiana del rumen. Los efectos beneficiosos de la monensina se han asociado a la producción de precursores gluconeogénicos a nivel ruminal, lo que originaría mayor disponibilidad de glucosa y la consiguiente mejora del estatus energético. Con el uso de monensina, a nivel sanguíneo se ha observado un descenso de β-hidroxibutirato, y ácidos grasos no esterificados. También han sido atribuidos efectos beneficiosos sobre la funcionalidad hepática, la absorción de ciertos minerales, la función inmune y la excreción de metano. En definitiva, el efecto positivo de la MON sobre el balance energético y la utilización de nutrientes reduciría la movilización de reservas tisulares, minimizando el riesgo de desórdenes metabólicos, mejorando la salud y por tanto el rendimiento de la vaca lechera. The aim of this research was to carry out a review of the use of monensin in dairy cows as a choice to approach more successfully the transition period. In dairy cows, the transition for the pregnancy to the beginning of lactation is a critical period which is characterized by display a higher incidence of diseases. The risk of metabolic disorders and other diseases during this time is allied to the state of negative energy balance in which the cow is, fact that involves a mobilization of nutrients from the tissue reserves. One of the possible solutions to improve the nutrient balance during the transition period is based on dispense ionophores such as monensin who modify the microbial population of the rumen. The beneficial effects of monensin have been associated with the production of gluconeogenic precursors at the ruminal level which would lead to greater availability of glucose and the consequent improvement of the energetic status. At the blood level it has been noted a decrease of β-hydroxybutyrate and non-esterified fatty acids. Beneficial effects have also been attributed to liver function, absorption of certain minerals and immune function.In brief, the positive effect of monensin on the energy balance and the use of nutrients would reduce the mobilization of tissue reserves, playing down the risk of metabolic disorders, improving the health and therefore the performance of the dairy cow.


2019 ◽  
Vol 19 (19) ◽  
pp. 1611-1626 ◽  
Author(s):  
Xiang-Li Bai ◽  
Xiu-Ling Deng ◽  
Guang-Jie Wu ◽  
Wen-Jing Li ◽  
Si Jin

Over the past three decades, the knowledge gained about the mechanisms that underpin the potential use of Rhodiola in stress- and ageing-associated disorders has increased, and provided a universal framework for studies that focused on the use of Rhodiola in preventing or curing metabolic diseases. Of particular interest is the emerging role of Rhodiola in the maintenance of energy homeostasis. Moreover, over the last two decades, great efforts have been undertaken to unravel the underlying mechanisms of action of Rhodiola in the treatment of metabolic disorders. Extracts of Rhodiola and salidroside, the most abundant active compound in Rhodiola, are suggested to provide a beneficial effect in mental, behavioral, and metabolic disorders. Both in vivo and ex vivo studies, Rhodiola extracts and salidroside ameliorate metabolic disorders when administered acutely or prior to experimental injury. The mechanism involved includes multi-target effects by modulating various synergistic pathways that control oxidative stress, inflammation, mitochondria, autophagy, and cell death, as well as AMPK signaling that is associated with possible beneficial effects on metabolic disorders. However, evidence-based data supporting the effectiveness of Rhodiola or salidroside in treating metabolic disorders is limited. Therefore, a comprehensive review of available trials showing putative treatment strategies of metabolic disorders that include both clinical effective perspectives and fundamental molecular mechanisms is warranted. This review highlights studies that focus on the potential role of Rhodiola extracts and salidroside in type 2 diabetes and atherosclerosis, the two most common metabolic diseases.


PPAR Research ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-14 ◽  
Author(s):  
Min-Chul Cho ◽  
Kyoung Lee ◽  
Sang-Gi Paik ◽  
Do-Young Yoon

Overweight and obesity lead to an increased risk for metabolic disorders such as impaired glucose regulation/insulin resistance, dyslipidemia, and hypertension. Several molecular drug targets with potential to prevent or treat metabolic disorders have been revealed. Interestingly, the activation of peroxisome proliferator-activated receptor (PPAR), which belongs to the nuclear receptor superfamily, has many beneficial clinical effects. PPAR directly modulates gene expression by binding to a specific ligand. All PPAR subtypes (α,γ,andσ) are involved in glucose metabolism, lipid metabolism, and energy balance. PPAR agonists play an important role in therapeutic aspects of metabolic disorders. However, undesired effects of the existing PPAR agonists have been reported. A great deal of recent research has focused on the discovery of new PPAR modulators with more beneficial effects and more safety without producing undesired side effects. Herein, we briefly review the roles of PPAR in metabolic disorders, the effects of PPAR modulators in metabolic disorders, and the technologies with which to discover new PPAR modulators.


Sign in / Sign up

Export Citation Format

Share Document